MRF help researchers in Spain to uncover the shocking lifelong costs of meningococcal disease
06 August 2014
New research undertaken in collaboration with the University of Barcelona has revealed how costs associated with surviving meningococcal disease with severe disability, such as amputations or brain damage, place an important burden on health budgets and governmental resources in Spain.
The research, published in Vaccine
, shows that costs at a national level can range from €2.3 to €3.2 million over a lifetime.
In 2013 MRF published research which showed that the costs to government associated with severe cases of meningococcal meningitis and septicaemia in the UK were in the region of £3 to £4.5 million over a lifetime.
Since then, we have helped some of our European colleagues in both France and Spain to undertake a similar exercise. Although the French research is still unpublished, a poster detailing the research won an award for outstanding quality at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Annual European Congress held in Dublin from 2-6 November 2013.